DONGWHA Pharm Research Institute, 35-71, Topsil-ro, Giheung-gu, Yongin-si 17084, Republic of Korea.
Department of Family Medicine, Seoul Paik Hospital, College of Medicine, Inje University, 9, Mareunnae-ro, Jung-gu, Seoul 04551, Republic of Korea.
Nutrients. 2023 Jul 7;15(13):3074. doi: 10.3390/nu15133074.
Obesity is a global health problem that affects the quality of life. It is a multidimensional chronic risk factor for major medical conditions, such as cardiovascular diseases, diabetes, and cancer. This clinical trial evaluated the efficacy of OK67 (DW2010), a lactic acid bacterium, in reducing body and visceral fat in overweight individuals (body mass index ≥25 kg/m and <30 kg/m), aged 20-60 years. A total of 100 subjects placed in a lifestyle modification program were randomly assigned to receive either DW2010 (2.0 g/day, 1.0 × 10 CFU) or a placebo for 12 weeks. The efficacy of DW2010 was evaluated by measuring body fat mass using dual-energy X-ray absorptiometry and visceral fat area using computed tomography. After 12 weeks, the change in body fat in the DW2010 group was not markedly different from that in the placebo group. However, visceral fat area decreased more in the DW2010 group than in the placebo group ( = 0.035). During the clinical trial, no major adverse events were reported. Moreover, no statistical differences were observed in the biochemical parameters of the DW2010 and placebo groups. Overall, we concluded that the intake of DW2010 for 12 weeks is safe and potentially reduces visceral fat in lifestyle-modified overweight subjects.
肥胖是一个全球性的健康问题，影响着生活质量。它是多种主要医疗状况的慢性风险因素，如心血管疾病、糖尿病和癌症。这项临床试验评估了 OK67（DW2010），一种乳酸菌，在减少超重人群（体重指数≥25 kg/m 且<30 kg/m）的体脂和内脏脂肪方面的功效，年龄在 20-60 岁之间。总共 100 名被置于生活方式改变计划中的受试者被随机分配接受 DW2010（2.0 g/天，1.0×10 CFU）或安慰剂，为期 12 周。通过双能 X 射线吸收法测量体脂肪量和计算机断层扫描测量内脏脂肪面积来评估 DW2010 的功效。在 12 周后，DW2010 组的体脂肪变化与安慰剂组无明显差异。然而，DW2010 组的内脏脂肪面积比安慰剂组减少更多（=0.035）。在临床试验期间，未报告重大不良事件。此外，DW2010 和安慰剂组的生化参数无统计学差异。总的来说，我们得出结论，摄入 DW2010 12 周是安全的，并且可能减少生活方式改变的超重受试者的内脏脂肪。
